STOCK TITAN

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

Puma Biotechnology, Inc. (Nasdaq: PBYI) announced the approval of inducement restricted stock unit awards covering 16,375 shares to three new non-executive employees as of September 1, 2021. This grant, made under the 2017 Employment Inducement Incentive Award Plan, vests over three years, with one-third vesting on the first anniversary and the remainder vesting bi-annually. This move aligns with Nasdaq Listing Rule 5635(c)(4), aimed at attracting talent to enhance the company's operations in cancer care development and commercialization.

Positive
  • Grant of restricted stock units may attract talent to the company.
  • Equity awards incentivize long-term commitment from new employees.
Negative
  • None.

LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that on September 1, 2021, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 16,375 shares of Puma common stock to three new non-executive employees.

The award was granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award’s vesting commencement date, September 1, 2021, and one-sixth of the shares underlying each award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500

info@pumabiotechnology.com

ir@pumabiotechnology.com

Source: Puma Biotechnology, Inc.

FAQ

What did Puma Biotechnology announce on September 1, 2021?

Puma Biotechnology announced the grant of inducement restricted stock unit awards covering 16,375 shares to three new non-executive employees.

How long will the restricted stock units vest for Puma Biotechnology's new employees?

The restricted stock units will vest over three years, with one-third vesting on the first anniversary and the remainder vesting bi-annually.

Which Nasdaq rule allows Puma Biotechnology to grant these stock awards?

The awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4), which allows for equity awards to new employees.

What is the purpose of the inducement stock awards at Puma Biotechnology?

The inducement stock awards are aimed at attracting talent to the company, enhancing its operational capacity.

PUMA BIOTECHNOLOGY INC

NASDAQ:PBYI

PBYI Rankings

PBYI Latest News

PBYI Stock Data

139.80M
38.59M
15.14%
67.8%
6.08%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
LOS ANGELES